TY  - GEN
AU  - Lim,Wah-Seng
AU  - Tardi,Paul G
AU  - Xie,Xiaowei
AU  - Fan,Mannie
AU  - Huang,Ruby
AU  - Ciofani,Travis
AU  - Harasym,Troy O
AU  - Mayer,Lawrence D
TI  - Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts
SN  - 1029-2403
PY  - 2010///1116
KW  - Animals
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - pharmacokinetics
KW  - Bone Marrow Cells
KW  - drug effects
KW  - Chemistry, Pharmaceutical
KW  - Cytarabine
KW  - administration & dosage
KW  - DNA-Binding Proteins
KW  - physiology
KW  - Daunorubicin
KW  - Dosage Forms
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Drug Synergism
KW  - Female
KW  - Flow Cytometry
KW  - Humans
KW  - Liposomes
KW  - Maximum Tolerated Dose
KW  - Mice
KW  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
KW  - drug therapy
KW  - Survival Rate
KW  - Tissue Distribution
KW  - Tumor Cells, Cultured
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.3109/10428194.2010.490312
ER  -